CRBP Corbus Pharmaceuticals Holdings, Inc. Insider Trading

Corbus Pharma Chief Business Officer buys 13,500 shares for $101,218.50 across two June transactions

Nishant C Saxena purchased 13,500 shares in two separate transactions at an average price of $7.50, a modest premium to the current price of $7.38. The stock is down 64.1% from its 52-week high of $20.56 and down 29.8% over the past 30 days. The company generated $0.00 in revenue in its latest quarter, reported a net loss of $-22,969,000.00 for the full year, and experienced -100.0% annual revenue growth, indicating a company in financial distress with no active commercial operations. While the insider's holdings increased by 21.8%, the timing follows a steep recent decline and comes amid fundamental deterioration, making the significance of this purchase unclear without visibility into whether this represents routine capital allocation or a targeted response to distressed conditions.

Cormorant Asset Mgmt buys 350,000 CRBP shares in 6 transactions for $7.0M; stock down 70.2% YTD, company unprofitable, -100% revenue decline.

Cormorant Asset Management acquired 350,000 shares in 6 separate open-market purchases on 2024-09-20 for $7,003,760.62, raising its stake to 2,375,000 shares (+17.3% from pre-transaction holdings). The acquisition spans prices from $17.48 to $22.23 per share, with a blended average of $20.01, significantly above the current price of $18.34. Corbus Pharmaceuticals is facing severe operational headwinds: latest quarter revenue was $0.00, annual revenue growth contracted -100.0%, and the company reported net income of -$9,997,000 over its most recent full fiscal year. Against this backdrop, the stock has declined 70.2% from its 52-week high and 69.3% over 30 days. In prior trades at CRBP (3 buys on 2024-03-08), Cormorant's 90-day outcomes were positive (returns of +1.4%, +7.7%, and +10.3%), suggesting a pattern of well-timed entry points at this ticker; however, the current macroeconomic and operational context differs materially from those prior purchases six months ago. Investors should monitor whether this accumulation reflects confidence in a turnaround or is driven by other factors, given the company's present unprofitability and revenue collapse.

CEO Cohen Yuval sold 63,358 shares for $2,950,518.18 via scheduled 10b5-1 plan (adopted 2024-03-15); holding reduced to 77,221 shares post-transaction

Cohen Yuval, CEO of Corbus Pharmaceuticals, executed 8 separate sales totaling 63,358 shares for $2,950,518.18 across three trading days (2024-06-14 through 2024-06-18) at prices ranging from $42.24 to $50.17. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-03-15, meaning the sales were scheduled in advance rather than discretionary. The sales reduced his holdings by 45.1% relative to pre-transaction holdings, from 140,579 shares to 77,221 shares. As a scheduled disposition under a 10b5-1 plan, this filing reflects execution of a pre-established program rather than a current-date signal about the insider's assessment of company value.

CFO Sean F. Moran sells 18,043 shares of CRBP for $863.8K via scheduled 10b5-1 plan (executed 06/14-06/18)

Sean F. Moran, Chief Financial Officer of Corbus Pharmaceuticals, executed 4 separate sales totaling 18,043 shares for $863,837.59 across a three-trading-day window (June 14-18, 2024) at a blended average price of $47.88. The transaction prices ranged from $49.87 to $42.12, reflecting modest price movement during execution. This sale reduced his holdings from 66,648 shares to 48,605 shares, a reduction of 27.1% of his pre-transaction position. Critically, these sales were executed under a pre-arranged 10b5-1 trading plan adopted on 2024-03-15, meaning they were scheduled and mechanical rather than discretionary decisions. For investors, the scheduled nature of this transaction removes it from the category of insider choice and timing signal; the pattern reflects a predetermined divestment program established three months prior.